Adaptin Bio completes reverse merger and $7.7M private placement for glioblastoma trial

ADAPTIN BIO, INC.

Reverse merger of Unite Acquisition 1 Corp. subsidiary with Adaptin; Adaptin survives and will trade on OTC Markets.
Private placement of 1,400,342 shares with Series A (1-yr, $4.40) and Series B (5-yr, $6.60) warrants.
$1.5M promissory notes converted at $3.30/share; total gross proceeds ~$7.7M.
Proceeds to fund Phase 1 trial of APTN-101 for glioblastoma after FDA IND clearance.
Post-closing: Lucius Partners and former Adaptin holders each hold ~3.25M shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.